Drug Type Microbiota |
Synonyms + [2] |
Mechanism NOD2 agonists(Nucleotide-binding oligomerization domain-containing protein 2 agonists), STING agonists(Stimulator of interferon genes agonists), TLR modulators(Toll-like receptor modulators) + [5] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | 19 Apr 2024 | |
Colorectal Cancer | Preclinical | US | 19 Apr 2024 | |
Hepatocellular Carcinoma | Preclinical | US | 19 Apr 2024 | |
Non-Hodgkin Lymphoma | Preclinical | US | 19 Apr 2024 | |
Pancreatic Cancer | Preclinical | US | 19 Apr 2024 | |
Multiple Primary Neoplasms | Preclinical | US | - |